Formulation of cidofovir improves the anti-papillomaviral activity of topical treatments in the CRPV/rabbit model

Neil Christensen, Nancy M. Cladel, Jiafen Hu, Karla K. Balogh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Current topical treatments for papillomas use ablative, cytotoxic and immunomodulating strategies and reagents. However, the effectiveness of topical treatments using different formulations has not been examined in preclinical models or clinical trials. The purpose of this study was to determine whether formulation of the small molecule acyclic nucleoside, cidofovir (CDV), could lead to improved therapeutic endpoints following topical treatment of papillomas using the cottontail rabbit papillomavirus (CRPV)/rabbit model. Different formulations with a set dose of 1% cidofovir were tested to establish comparative data. The results demonstrated that anti-papilloma treatments with topical CDV were greatly enhanced when formulated versus unformulated. Best results were obtained with CDV formulated in cremophor, then in Carbomer 940, and then in DMSO. Further studies indicated that effective formulations led to complete cures of papillomas at dilutions less than 0.3% CDV. These studies together with previous observations demonstrated that unformulated CDV under the same treatment regime required doses of 2% to achieve cures demonstrating that much less compound can be used when properly formulated.

Original languageEnglish (US)
Pages (from-to)148-155
Number of pages8
JournalAntiviral Research
Volume108
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Cottontail rabbit papillomavirus
Papilloma
Rabbits
carbopol 940
Dimethyl Sulfoxide
Nucleosides
cidofovir
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Virology
  • Pharmacology
  • Medicine(all)

Cite this

@article{12f5a7b29e234cf0a059dac000483a73,
title = "Formulation of cidofovir improves the anti-papillomaviral activity of topical treatments in the CRPV/rabbit model",
abstract = "Current topical treatments for papillomas use ablative, cytotoxic and immunomodulating strategies and reagents. However, the effectiveness of topical treatments using different formulations has not been examined in preclinical models or clinical trials. The purpose of this study was to determine whether formulation of the small molecule acyclic nucleoside, cidofovir (CDV), could lead to improved therapeutic endpoints following topical treatment of papillomas using the cottontail rabbit papillomavirus (CRPV)/rabbit model. Different formulations with a set dose of 1{\%} cidofovir were tested to establish comparative data. The results demonstrated that anti-papilloma treatments with topical CDV were greatly enhanced when formulated versus unformulated. Best results were obtained with CDV formulated in cremophor, then in Carbomer 940, and then in DMSO. Further studies indicated that effective formulations led to complete cures of papillomas at dilutions less than 0.3{\%} CDV. These studies together with previous observations demonstrated that unformulated CDV under the same treatment regime required doses of 2{\%} to achieve cures demonstrating that much less compound can be used when properly formulated.",
author = "Neil Christensen and Cladel, {Nancy M.} and Jiafen Hu and Balogh, {Karla K.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.antiviral.2014.06.001",
language = "English (US)",
volume = "108",
pages = "148--155",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "1",

}

Formulation of cidofovir improves the anti-papillomaviral activity of topical treatments in the CRPV/rabbit model. / Christensen, Neil; Cladel, Nancy M.; Hu, Jiafen; Balogh, Karla K.

In: Antiviral Research, Vol. 108, No. 1, 01.01.2014, p. 148-155.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Formulation of cidofovir improves the anti-papillomaviral activity of topical treatments in the CRPV/rabbit model

AU - Christensen, Neil

AU - Cladel, Nancy M.

AU - Hu, Jiafen

AU - Balogh, Karla K.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Current topical treatments for papillomas use ablative, cytotoxic and immunomodulating strategies and reagents. However, the effectiveness of topical treatments using different formulations has not been examined in preclinical models or clinical trials. The purpose of this study was to determine whether formulation of the small molecule acyclic nucleoside, cidofovir (CDV), could lead to improved therapeutic endpoints following topical treatment of papillomas using the cottontail rabbit papillomavirus (CRPV)/rabbit model. Different formulations with a set dose of 1% cidofovir were tested to establish comparative data. The results demonstrated that anti-papilloma treatments with topical CDV were greatly enhanced when formulated versus unformulated. Best results were obtained with CDV formulated in cremophor, then in Carbomer 940, and then in DMSO. Further studies indicated that effective formulations led to complete cures of papillomas at dilutions less than 0.3% CDV. These studies together with previous observations demonstrated that unformulated CDV under the same treatment regime required doses of 2% to achieve cures demonstrating that much less compound can be used when properly formulated.

AB - Current topical treatments for papillomas use ablative, cytotoxic and immunomodulating strategies and reagents. However, the effectiveness of topical treatments using different formulations has not been examined in preclinical models or clinical trials. The purpose of this study was to determine whether formulation of the small molecule acyclic nucleoside, cidofovir (CDV), could lead to improved therapeutic endpoints following topical treatment of papillomas using the cottontail rabbit papillomavirus (CRPV)/rabbit model. Different formulations with a set dose of 1% cidofovir were tested to establish comparative data. The results demonstrated that anti-papilloma treatments with topical CDV were greatly enhanced when formulated versus unformulated. Best results were obtained with CDV formulated in cremophor, then in Carbomer 940, and then in DMSO. Further studies indicated that effective formulations led to complete cures of papillomas at dilutions less than 0.3% CDV. These studies together with previous observations demonstrated that unformulated CDV under the same treatment regime required doses of 2% to achieve cures demonstrating that much less compound can be used when properly formulated.

UR - http://www.scopus.com/inward/record.url?scp=84903631566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903631566&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2014.06.001

DO - 10.1016/j.antiviral.2014.06.001

M3 - Article

C2 - 24946003

AN - SCOPUS:84903631566

VL - 108

SP - 148

EP - 155

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 1

ER -